МЕДИКАМЕНТОЗНОЕ ЛЕЧЕНИЕ ПАЦИЕНТОВ С АКРОМЕГАЛИЕЙ, ЧАСТИЧНО РЕЗИСТЕНТНЫХ К ТЕРАПИИ АНАЛОГАМИ СОМАТОСТАТИНА
- Авторы: Анциферов М.Б.1, Пронин ВС2, Алексеева ТМ1, Antciferov MB3, Pronin VS3, M T3
-
Учреждения:
- Эндокринологический диспансер Департамента здравоохранения г. Москвы
- Первый МГМУ им. И.М. Сеченова
- Выпуск: № 16 (2011)
- Страницы: 49-55
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/279010
- ID: 279010
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
Михаил Борисович Анциферов
Эндокринологический диспансер Департамента здравоохранения г. МосквыЭндокринологический диспансер Департамента здравоохранения г. Москвы
В С Пронин
Первый МГМУ им. И.М. СеченоваПервый МГМУ им. И.М. Сеченова
Т М Алексеева
Эндокринологический диспансер Департамента здравоохранения г. МосквыЭндокринологический диспансер Департамента здравоохранения г. Москвы
M B Antciferov
V S Pronin
T M
Список литературы
- Reilchlin S, 1987. Etiology of acromegaly from the neuroendocrine point of view: a historical perspective. In Acromegaly: A Century of Scientific and Clinical Progress, pp. 7 - 15, Eds RJ Robbins & S Melmed. Plenum Press, New York, NY, USA.
- Freda PU. Acromegaly. Aims of treatment. In: Acromegaly. A handbook of history, current therapy and future prospects, 2009. P. 102.
- Clemmons DR, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003;88:4759-67.
- Beckers A, Daly A. The epidemiology of acromegaly. In: Acromegaly. A handbook of history, current therapy and future prospects, 2009. P. 16.
- Holdway IM, Rajasoora RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74.
- Swearingen B, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26.
- Bates PR, Carson MN, Trainer PJ, et al. Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol 2008;68:136-42.
- Bates AS, Van't Hoff W, et al. An oudit of outcome of teratment in acromegaly. Q J Med 1993;86:293-99.
- Murray RD, et al. Critical Analisysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly. J Clin Endocrinol Metab 2008;93:2957-68.
- Freda PU, Katznelson L, van der Lely AJ, et al. Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analisis. J Clin Endocrinol Metab 2005;90:4465-73.
- Neggers S, Lamberts S, van der Lely AJ. Acromegaly. Long-term treatment. In: Acromegaly. A handbook of history, current therapy and future prospects, 2009. p. 183.
- Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Springer, Pituitary. DOI 10.1007/s 11102-010-0282-z. Published online: 2010. December 15.
- van der Lely AJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9.
- Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92:4598-601.
- Sandret L, Maison P, Chanson P. Place of Cabergoline in Acromegaly: A meta-Analisis. J Clin Endocrinol Metab 2011;96(5):1327-35.
- Colao A, et al. Beneficial effect of dose escalation of Octreotid-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157:579-87.
- Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009;161:331-38.
- Auk J, Seppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord 2008;9:33-9.
- Wuster C, Both S, et al. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Reports 2010;4:85.
- Attanisio R, Lanzi R, et al. Effects of lanreotide Autogel on growth hormone, insulilike growth factor 1, and tumor size in acromegaly: a 1 - year prospective multicenter study. Endocrinol Pract 2008;14:846-55.
- Toledano Y, Rot L, Greenman Y, et al. Efficacy of long-term lanreotide teratment in patients with acromegaly. Pituitary 2009;12:285-93.
- Feenstra J, de Herder WW, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in acromegaly. J Clin Endocrinol Metab 2005;92:4598-601.
- Neggers SJCM , et al. Qualyty of life in Acromegalic Patients during Long-term Somatostatin Analog Treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93:3853-59.
- Abs R, et al. Carbegoline in the Treatment of the Acromegaly: A Study in 64 patients. J Clin Endocrinol Metab 1998;83:374-78.
- Cozzi R, et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol 2004;61:209-15.
- Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005;152:569-74.
- Sandret L, Maison P, Chanson P. Place of Cabergoline in Acromegaly: A meta-Analisis. J Clin Endocr Metabolosm 2011;96(5):1327-35.
- Comparative therapeutic efficacy of Autogel, the new somatostatin analogue of lanreotide's prolonged release form, in acromegalic patients responders to somatostatin. Final version: 09 November 2004.
- Cendors JM, et al. Pharmacokinetics and population pharmacodinamic analisis of lanreotide Autogel. Metab Clin Experim 2005;54:1276-81.
- Attanisio R, et al. Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1n and tumor size in acromegaly: A 1-year prospective multicenter study. Endocr Practice 2008;14:846-55.
Дополнительные файлы
![](/img/style/loading.gif)